The BAG2 Knockout A-549 Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 lung adenocarcinoma cell line. This product features a targeted disruption of BAG2, which encodes a co-chaperone that negatively regulates HSP70 chaperone activity and promotes ubiquitin-proteasome degradation of misfolded proteins. The polyclonal knockout pool ensures a heterogeneous population of cells carrying the intended loss-of-function modification, suitable for studying BAG2-dependent processes without single-cell clonal selection. This model eliminates the need for clone isolation while offering a genetically diverse background for robust functional assays.
A-549 cells originate from a 58-year-old male patient with lung adenocarcinoma and harbor a KRAS mutation, making them a widely utilized model in oncology and respiratory research. As epithelial cells derived from alveolar tissue, they retain features of pulmonary surfactant secretion and are extensively employed to investigate lung cancer biology, drug responses, and stress signaling. Their well-characterized genetic and phenotypic properties provide a reliable platform for gene-editing studies, enabling the dissection of molecular mechanisms underlying tumorigenesis, chemoresistance, and cellular homeostasis in a physiologically relevant context.
BAG2 functions as a critical co-chaperone that binds HSP70/HSC70 and promotes the release of substrates for ubiquitin-proteasomal degradation. It is negatively regulated by proteotoxic stress and is transcriptionally activated by heat shock factor 1 (HSF1) and NF-??B signaling. Through its interaction with CHIP/STUB1, BAG2 facilitates the clearance of misfolded proteins such as tau and ??-synuclein. Disruption of BAG2 leads to reduced HSP70 chaperone activity, enhanced ubiquitin-proteasome degradation, and modulation of NF-??B target genes including Bcl-2 and IAPs, thereby altering the balance between survival and apoptosis.
In the A-549 lung adenocarcinoma context, BAG2 knockout disrupts protein quality control and sensitizes cells to stress-induced apoptosis by perturbing NF-??B anti-apoptotic signaling. This dysregulation can impact chemoresistance, as BAG2-mediated protection against proteotoxic stress is often exploited by cancer cells to survive chemotherapy. Consequently, these polyclonal knockout cells represent a valuable model for examining how loss of BAG2 influences tumor cell vulnerability to proteasome inhibitors, oxidative stress, and other therapeutic insults, and for dissecting the interplay between chaperone networks and oncogenic signaling.
Researchers can employ these cells in a variety of advanced experimental workflows. Common applications include chemoresistance studies, protein aggregation analysis using ubiquitination assays, and interrogation of NF-??B signaling via reporter assays. Additional relevant techniques include Western blot and RT-qPCR for assessing BAG2 expression, co-immunoprecipitation to confirm BAG2-HSP70 interactions, and apoptosis assays such as Annexin V/PI staining. Cell viability assays under proteotoxic stress and proteasome activity measurements further support drug screening for proteasome modulators or HSP70 inhibitors. For further technical details or custom solutions, please contact Ascent Research.
